VirnetX (VHC -10.1%) is tumbling to fresh 52-week lows on strong volume, as the Street continues weighing the fallout of an adverse jury ruling in its patent suit against Cisco. Last week, the judge presiding over the suit issued a final judgment declaring 12 VirnetX patent claims are not invalid, and denying all pending motions. [View news story]
Disgusted with the lack of journalistic integrity. How about sending out a new email blast with the correction highlighted? And how about using clear language like "VALID" instead of a double negative? Honestly, how in the world do you sleep at night? Karma, my friend, karma. . .
VirnetX (VHC) -3.5% AH after the ITC decides not to review an administrative law judge's decision to end an investigation into a patent infringement complaint against Apple (AAPL), citing a "lack of standing." VirnetX had filed a petition asking for the decision to be overturned. (ITC ruling - PDF) [View news story]
$VHC is refiling this complaint. This has no bearing on the court case in Tyler Texas being held in November, 2012. No worries.
Apple Sanctioned In VirnetX Patent Case For Obstructing 'Unfavorable Testimony' [View article]
Dustin, this is a great report to bring investors up-to-date on the sanctions placed upon Apple. Apple is damned either way (and quite frankly, I can't decide which I'd rather they choose. And as to the comment that Apple's engineer could just take the stand and state, "I don't remember" or "I don't know" that is not an option as this engineer is an educated man who tried to patent what VHC had patented years before him. Judge Davis would never stand for that and even more severe sanctions would be implemented.
No 'Shareholder Uprising' at Dendreon [View article]
Thanks Saul for setting the record straight. I'm long and strong DNDN, and plan on remaining so as sales build over the next few years. The Board of Directors of Dendreon should be commended for the job they have done in getting Provenge out of the lab and into the immune systems of patients, all while preserving 100% of the rights worldwide.
Great factual article Saul. It's clear sailing for Dendreon and for prostate cancer patients. As happy as I am for Dendreon shareholders, I'm even happier for cancer patients. This is just the beginning as we move forward towards making cancer a chronic, treatable condition instead of a death sentence.
Well Saul you took the words right out of my mouth. When I read the Motley Fool article, I immediately had the same reaction as you - why did Motley Fool allow the misleading headline on their website? Only one reason, increased hits on their site. Is there no such thing as INTEGRITY? Thanks again for getting the real facts out for Dendreon.
Love reading your articles and this is another excellent one, Saul. Thanks for your voice of reason, dispelling the FUD out there, spread by those who want to manipulate share price. I've forwarded this article on to friends and family.
Still a Lot of Potential in Dendreon and the Cancer Immunotherapy Market [View article]
Must correct the inaccuracies of Fourstarz comments . . . first off, patients on Provenge do not have "barely tolerable existance" or "little quality". That is part of the beauty of Provenge. Side effects for the three infusions required are chills and/or slight fever for one to two days following each infusion. That is it. No hair loss, nausea, vomiting, etc as one would get with chemo. Patients are enjoying improved quality of life with Provenge. Additionally, the average increase in life was 4.1 months, not 3 months as stated by Fourstarz. Many of the men in the clinical trial were alive 3 years after receiving Provenge. It is obvious that Fourstarz has not spent any time actually researching Dendreon and their cancer vaccine for prostate cancer, Provenge before writing a comment.
Transcept Pharma (TSPT) Offers an Interesting Biotech Value Play [View instapost]
Nice analysis Advalorem! Transcept's Intermezzo is a winner, millions of American's need a middle of the night sleep aid. With Transcept's low number of outstanding shares, huge cash cushion, and big milestone and royalty payments from Purdue, I foresee a nice jump in share price with FDA approval.
3 Reasons Not to Predict FDA Action: Matrixx, Savient, Dendreon [View article]
Ruthanne, please understand why Dendreonites are so touchy . . . too many lies have been told about Provenge and Dendreon by other authors and so called analysts. It seems anyone can claim to be a journalist but few bother to check out the facts. I agree that the FDA is unpredictable but they wouldn't dare not approve Provenge this time, too many men have died prematurely already in the name of greed.
FDA Calendar Updates: Transcept Pharma Surges on Deal [View article]
I have liked Transcept for some time now, their product, Intermezzo, is very clever. It allows one to fall back to sleep in the middle of the night, yet wake up on time in the morning refreshed. I know there are times I would like that product on my nightstand. TSPT had plenty of cash on the balance sheet and now with this deal, they are loaded.
"there were six participants that died as a result of heart problems associated with the drug (as opposed to 3 on the placebo)"
You do understand that there were 4 patients receiving Krystexxa for every 1 patient on placebo? Statistically that would make the placebo more dangerous than Krystexxa.
VirnetX (VHC -10.1%) is tumbling to fresh 52-week lows on strong volume, as the Street continues weighing the fallout of an adverse jury ruling in its patent suit against Cisco. Last week, the judge presiding over the suit issued a final judgment declaring 12 VirnetX patent claims are not invalid, and denying all pending motions. [View news story]
VirnetX (VHC) -3.5% AH after the ITC decides not to review an administrative law judge's decision to end an investigation into a patent infringement complaint against Apple (AAPL), citing a "lack of standing." VirnetX had filed a petition asking for the decision to be overturned. (ITC ruling - PDF) [View news story]
Apple Sanctioned In VirnetX Patent Case For Obstructing 'Unfavorable Testimony' [View article]
VHC's new patent provides leverage in potential buyout negotiations. [View instapost]
No 'Shareholder Uprising' at Dendreon [View article]
Why Dendreon Will Power Ahead Now [View article]
Dendreon Is Not In Trouble! [View instapost]
Dendreon Update [View instapost]
Dendreon, The Fabled "Next Amgen" [View instapost]
Dendreon: Fear is Our Friend [View instapost]
Still a Lot of Potential in Dendreon and the Cancer Immunotherapy Market [View article]
Transcept Pharma (TSPT) Offers an Interesting Biotech Value Play [View instapost]
3 Reasons Not to Predict FDA Action: Matrixx, Savient, Dendreon [View article]
FDA Calendar Updates: Transcept Pharma Surges on Deal [View article]
Savient Up Big on Friday [View article]
You do understand that there were 4 patients receiving Krystexxa for every 1 patient on placebo? Statistically that would make the placebo more dangerous than Krystexxa.